Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Shares Outstanding (2016 - 2025)

Historic Shares Outstanding for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $108.2 million.

  • Rocket Pharmaceuticals' Shares Outstanding rose 1875.83% to $108.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.2 million, marking a year-over-year increase of 1875.83%. This contributed to the annual value of $106.5 million for FY2024, which is 1791.22% up from last year.
  • According to the latest figures from Q3 2025, Rocket Pharmaceuticals' Shares Outstanding is $108.2 million, which was up 1875.83% from $107.9 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' Shares Outstanding's 5-year high stood at $108.2 million during Q3 2025, with a 5-year trough of $62.0 million in Q1 2021.
  • For the 5-year period, Rocket Pharmaceuticals' Shares Outstanding averaged around $82.9 million, with its median value being $80.5 million (2023).
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Shares Outstanding skyrocketed by 3288.35% in 2023, and later skyrocketed by 107.61% in 2024.
  • Rocket Pharmaceuticals' Shares Outstanding (Quarter) stood at $64.5 million in 2021, then grew by 22.66% to $79.1 million in 2022, then rose by 14.1% to $90.3 million in 2023, then increased by 17.91% to $106.5 million in 2024, then rose by 1.65% to $108.2 million in 2025.
  • Its Shares Outstanding stands at $108.2 million for Q3 2025, versus $107.9 million for Q2 2025 and $106.8 million for Q1 2025.